Price, Not Safety, Most Likely To Limit Avastin Use In Breast Cancer – JPMorgan Physician Survey
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-term revenue upside for drug in all indications could be as much as $6.5 billion by 2012, says JPMorgan analyst Geoffrey Meacham.